Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
Altamira Therapeutics (OTCQB:CYTOF) has entered into a collaboration agreement with an unnamed radiopharmaceutical company to evaluate its RNA delivery platform for radiopharmaceutical targeting in cancer treatment. The collaboration will test RNA nanoparticles in conjunction with the partner's proprietary radiopharmaceuticals both in vitro and in vivo.
Upon successful completion of experiments, the partner will have the option to negotiate a license and supply agreement for developing and commercializing the RNA nanoparticles in cancer treatment. The global radiopharmaceutical market reached $8.4 billion in 2024 and is projected to grow to $17.1 billion by 2033.
Radiopharmaceutical therapy utilizes small amounts of radioactive compounds that, when injected, travel through the bloodstream to bind to tumor-specific receptors for diagnosis and treatment of various diseases, particularly cancer.
Altamira Therapeutics (OTCQB:CYTOF) ha intrapreso un accordo di collaborazione con un'azienda di radiofarmaci non specificata per valutare la propria piattaforma di consegna dell'RNA per il targeting dei radiofarmaci nel trattamento del cancro. La collaborazione testerà nanoparticelle di RNA in congiunzione con i radiofarmaci proprietari del partner, sia in vitro che in vivo.
Al termine degli esperimenti con esito positivo, il partner avrà l'opzione di negoziare un contratto di licenza e fornitura per lo sviluppo e la commercializzazione delle nanoparticelle di RNA nel trattamento del cancro. Il mercato globale dei radiofarmaci ha raggiunto 8,4 miliardi di dollari nel 2024 e si prevede che crescerà fino a 17,1 miliardi di dollari entro il 2033.
La terapia radiofarmaceutica utilizza piccole quantità di composti radioattivi che, una volta iniettati, viaggiano attraverso il flusso sanguigno per legarsi ai recettori specifici per i tumori, per la diagnosi e il trattamento di varie malattie, in particolare il cancro.
Altamira Therapeutics (OTCQB:CYTOF) ha firmado un acuerdo de colaboración con una empresa de radiofármacos no identificada para evaluar su plataforma de entrega de ARN para la apuntación de radiofármacos en el tratamiento del cáncer. La colaboración probará nanopartículas de ARN en conjunto con los radiofármacos de propiedad del socio, tanto in vitro como in vivo.
Tras la exitosa finalización de los experimentos, el socio tendrá la opción de negociar un contrato de licencia y suministro para el desarrollo y la comercialización de las nanopartículas de ARN en el tratamiento del cáncer. El mercado global de radiofármacos alcanzó 8.4 mil millones de dólares en 2024 y se prevé que crezca hasta 17.1 mil millones de dólares para 2033.
La terapia con radiofármacos utiliza pequeñas cantidades de compuestos radiactivos que, al ser inyectados, viajan a través del torrente sanguíneo para unirse a receptores específicos de tumores para el diagnóstico y tratamiento de diversas enfermedades, particularmente el cáncer.
알타미라 테라퓨틱스 (OTCQB:CYTOF)는 알려지지 않은 방사선 의약품 회사와 협력 계약을 체결하여 암 치료를 위한 방사선 의약품 타겟팅을 위한 RNA 전달 플랫폼을 평가하고 있습니다. 이 협력은 파트너의 독점 방사선 의약품과 함께 RNA 나노입자를 시험할 것입니다. 시험은 병행하여 생체 내외에서 진행됩니다.
실험이 성공적으로 완료될 경우, 파트너는 RNA 나노입자의 개발 및 상용화를 위한 라이선스 및 공급 계약을 협상할 옵션을 갖게 됩니다. 글로벌 방사선 의약품 시장은 2024년 84억 달러에 도달했으며, 2033년까지 171억 달러로 성장할 것으로 예상됩니다.
방사선 의약품 치료는 작은 양의 방사성 화합물을 사용하여 주사된 후 혈류를 통해 이동하여 종양 특이적 수용체에 결합하여 다양한 질병, 특히 암의 진단 및 치료에 사용됩니다.
Altamira Therapeutics (OTCQB:CYTOF) a conclu un accord de collaboration avec une entreprise de radio-pharmaceutiques non identifiée pour évaluer sa plateforme de livraison d'ARN destinée à la ciblage de radio-pharmaceutiques dans le traitement du cancer. La collaboration testera des nanoparticules d'ARN en association avec les radio-pharmaceutiques propriétaires du partenaire, à la fois in vitro et in vivo.
À l'issue des expériences réussies, le partenaire aura l'option de négocier un contrat de licence et de fourniture pour le développement et la commercialisation des nanoparticules d'ARN dans le traitement du cancer. Le marché mondial des radio-pharmaceutiques a atteint 8,4 milliards de dollars en 2024 et devrait croître pour atteindre 17,1 milliards de dollars d'ici 2033.
La thérapie radio-pharmaceutique utilise de petites quantités de composés radioactifs qui, une fois injectés, voyagent à travers la circulation sanguine pour se lier à des récepteurs spécifiques des tumeurs dans le but de diagnostiquer et traiter diverses maladies, en particulier le cancer.
Altamira Therapeutics (OTCQB:CYTOF) hat eine Zusammenarbeit mit einem nicht genannten Radiopharma-Unternehmen vereinbart, um seine RNA-Abgabetechnologie für die gezielte Therapie mit Radiopharmazeutika bei Krebserkrankungen zu bewerten. In dieser Zusammenarbeit werden RNA-Nanopartikel zusammen mit den proprietären Radiopharmazeutika des Partners sowohl in vitro als auch in vivo getestet.
Bei erfolgreichem Abschluss der Experimente hat der Partner die Möglichkeit, einen Lizenz- und Liefervertrag zur Entwicklung und Vermarktung der RNA-Nanopartikel für die Krebsbehandlung auszuhandeln. Der globale Markt für Radiopharmazeutika erreichte im Jahr 2024 8,4 Milliarden Dollar und wird bis 2033 voraussichtlich auf 17,1 Milliarden Dollar wachsen.
Die Radiopharmazeutische Therapie nutzt kleine Mengen radioaktiver Verbindungen, die nach der Injektion durch den Blutkreislauf reisen, um sich an tumorspezifische Rezeptoren zu binden, zur Diagnose und Behandlung verschiedener Krankheiten, insbesondere von Krebserkrankungen.
- Global radiopharmaceutical market shows strong growth potential from $8.4B (2024) to $17.1B (2033)
- Potential future licensing and supply agreement opportunity if experiments succeed
- None.
Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) --
- Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment
- Project collaboration partner will have option to negotiate licensing and supply agreement
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration agreement with a company in the radiopharmaceutical sector to evaluate the use of the Company’s proprietary RNA delivery platform for radiopharmaceutical targeting.
Radiopharmaceutical therapy uses tiny amounts of radioactive compounds (“radiopharmaceuticals” or “radioligands”) to diagnose and treat various diseases, in particular cancer. Once injected into the patient, the radiopharmaceutical finds its way to the tumor through the bloodstream and binds to a tumor-specific receptor. The global radiopharmaceutical market reached
Under the terms of the agreement, Altamira and its project collaboration partner intend to test in vitro and in vivo the use of nanoparticles with an undisclosed RNA payload in conjunction with one of the partner’s proprietary radiopharmaceuticals. Upon successful conclusion of the experiments, the partner will, under certain conditions, have the option to negotiate with Altamira a license and supply agreement to develop and commercialize the RNA nanoparticles for use in cancer treatment.
“We are very delighted to initiate this collaboration to explore the utility of our RNA delivery technology in conjunction with radiopharmaceuticals”, commented Thomas Meyer, PhD, Altamira’s founder, Chairman and Chief Executive Officer. “The concept of radiopharmaceutical therapy has allowed for highly impressive advances in treatment outcomes and holds great promise for expanding precision oncology to additional tumor types. We look forward to working with our partner, on further enhancing radiopharmaceuticals’ therapeutic benefits.”
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include but are not limited to the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
1 https://straitsresearch.com/report/radioligand-therapy-market
FAQ
What is the potential market size for Altamira's radiopharmaceutical collaboration by 2033?
What are the key terms of Altamira's (CYTOF) new collaboration agreement?
How does Altamira's (CYTOF) radiopharmaceutical technology work in cancer treatment?
What is the current market value of the radiopharmaceutical sector where CYTOF is expanding?
